Summary and Pipeline
We aim to discover and develop medicines that are transformational for patients
We are developing potential best-in-class orexin receptor 2 (OX2R) agonists intended to be orally administered for the treatment of sleep-wake disorders, including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), and other neurological, neurodegenerative, and neuropsychiatric conditions. We anticipate that our orexin agonists may have utility in treating impaired attention, cognitive deficits, fatigue and other symptoms. We also have an early-stage immuno-oncology program focused on our LockBody® technology platform.
Realizing Our Vision
We are working to discover unique opportunities to potentially address key medical needs
Orexin Receptor 2 Agonist Program
Dr. Mario Alberto Accardi, Chief Executive Officer of Centessa, is the principal architect of Centessa’s OX2R agonist program. Trained as a biomedical engineer, Dr. Accardi recognized early on the opportunity to use structure-based drug design to disrupt the conventional approach to treating sleep-wake disorders, excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms.
Click below to learn more about our orexin receptor 2 agonist program for sleep-wake disorders and other conditions.
LockBody® Technology Platform in Oncology
Dr. William Finlay, President of the Centessa LockBody Program and a widely published expert on antibody engineering, developed the LockBody® technology platform with the goal to redefine immuno-oncology treatment for patients with cancer.
Click below to learn more about our novel LockBody® platform in oncology.
Pipeline
Our Most Advanced Potential Best-in-Class / First-in-Class Medicines for Patients
Asset
Disease/Condition
Mechanism
Pre-clinical
Phase 1
Phase 2
Registrational
ORX750
Narcolepsy Type 1 (NT1)
OX2R Agonist
ORX750
Narcolepsy Type 2 (NT2)
OX2R Agonist
ORX750
Idiopathic Hypersomnia (IH)
OX2R Agonist
ORX142
Neurological & Neurodegenerative Disorders
OX2R Agonist
ORX489
Neuropsychiatric Disorders
OX2R Agonist
Centessa also has multiple early-stage assets including the LockBody® Technology Platform.
